Finance Watch: Venture Cash Flows For European Companies
Executive Summary
Private Company Edition: A new VC fund emerges for European biopharma firms and a previously announced fund gains a new UK investor. Also, Encoded Therapeutics leads recent venture financings with a $104m series C round.
You may also be interested in...
Exelixis Looks To Early-Stage Option Rights As Low-Risk Pipeline Expansion Play
The maker of Cabometyx wants to expand its oncology pipeline via deal-making but is wary of the high attrition rate in cancer. Option deals with Cybrexa and Sairopa may avoid some of that risk.
As Teva's Neurology Portfolio Gains Momentum, New Assets Join The Pipeline
Q3 results show Austedo appears headed towards blockbuster status, and the company signed a collaboration with MODAG for two compounds for neurodegenerative diseases.
Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.